Improvement of muscle strength in a mouse model for congenital myopathy treated with HDAC and DNA methyltransferase inhibitors

To date there are no therapies for patients with congenital myopathies, muscle disorders causing poor quality of life of affected individuals. In approximately 30% of the cases, patients with congenital myopathies carry either dominant or recessive mutations in the ryanodine receptor 1 (RYR1) gene;...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz, Alexis, Benucci, Sofia, Duthaler, Urs, Bachmann, Christoph, Franchini, Martina, Noreen, Faiza, Pietrangelo, Laura, Protasi, Feliciano, Treves, Susan, Zorzato, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956288/
https://www.ncbi.nlm.nih.gov/pubmed/35238775
http://dx.doi.org/10.7554/eLife.73718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956288/
https://www.ncbi.nlm.nih.gov/pubmed/35238775
http://dx.doi.org/10.7554/eLife.73718

Ejemplares similares